A randomized phase II trial investigated the effect of adding the Aurora kinase A inhibitor alisertib to a reduced dose of weekly paclitaxel in the treatment of patients with estrogen receptor–positive, ERBB2-negative, or triple-negative metastatic breast cancer. According to Joyce O’Shaughnessy, MD, and researchers from Baylor University Medical Center, Dallas, the combination treatment significantly improved progression-free survival compared with paclitaxel alone. Their findings were published in JAMA Network Open.